Identification of drug-induced toxicity biomarkers for treatment determination

scientific article published on 27 April 2015

Identification of drug-induced toxicity biomarkers for treatment determination is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1002/PST.1684
P698PubMed publication ID25914330

P50authorTzu-Pin LuQ60496620
P2093author name stringJames J Chen
P2860cites workIdentifying Important Risk Factors for Survival in Kidney Graft Failure Patients Using Random Survival ForestsQ22673963
Class-imbalanced classifiers for high-dimensional dataQ26822875
Gene expression profiling predicts clinical outcome of breast cancerQ27860732
The challenge of subgroup analyses--reporting without distortingQ28235374
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancerQ28297827
A framework for the use of genomics data at the EPA.Q31060259
Clinical trial designs for predictive marker validation in cancer treatment trialsQ33213015
Development of biomarker classifiers from high-dimensional dataQ33426749
Performance of novel kidney biomarkers in preclinical toxicity studiesQ33917932
Subgroup identification from randomized clinical trial dataQ33981752
Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategiesQ34192717
Power for tests of interaction: effect of raising the Type I error rateQ35874880
Idiosyncratic drug hepatotoxicityQ36148442
Blood gene expression signatures predict exposure levels.Q36156901
Why drugs fail--a study on side effects in new chemical entities.Q36296698
Development of the 21-gene assay and its application in clinical practice and clinical trialsQ37079600
Developing and Validating Continuous Genomic Signatures in Randomized Clinical Trials for Predictive MedicineQ37096663
Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges.Q37325013
Adaptive Clinical Trial Designs for Simultaneous Testing of Matched Diagnostics and TherapeuticsQ37368881
Integrating biomarkers in clinical trialsQ37853183
Clinical trials for predictive medicineQ38020126
Pharmacogenomic Biomarkers for Personalized MedicineQ38112822
A regulatory perspective on essential considerations in design and analysis of subgroups when correctly classifiedQ38176063
Tests for interaction in epidemiologic studies: A review and a study of powerQ40164602
Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trialsQ41187186
Identification and Elucidation of the Biology of Adverse Events: The Challenges of Safety Assessment and Translational MedicineQ46018188
The liver toxicity biomarker study: phase I design and preliminary results.Q46145573
Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction testQ47423638
Bayesian methods for design and analysis of safety trialsQ51180919
Biomarker Classifiers for Identifying Susceptible Subpopulations for Treatment DecisionsQ51467325
The mean does not mean as much anymore: finding sub-groups for tailored therapeuticsQ51675471
Toxicogenomics strategies for predicting drug toxicityQ51930594
A network solutionQ53527430
Gene Selection for Cancer Classification using Support Vector MachinesQ56535529
Toxicogenomics in Predictive Toxicology in Drug DevelopmentQ56854644
FDA-approved drug labeling for the study of drug-induced liver injuryQ57258176
P433issue4
P921main subjectbiomarkerQ864574
P304page(s)284-293
P577publication date2015-04-27
P1433published inPharmaceutical StatisticsQ7180744
P1476titleIdentification of drug-induced toxicity biomarkers for treatment determination
P478volume14

Reverse relations

Q35863520Subgroup identification for treatment selection in biomarker adaptive designcites workP2860

Search more.